Your browser is no longer supported. Please, upgrade your browser.
MYL Mylan N.V. daily Stock Chart
Mylan N.V.
IndexS&P 500 P/E43.41 EPS (ttm)0.44 Insider Own0.40% Shs Outstand517.90M Perf Week-1.56%
Market Cap9.82B Forward P/E4.18 EPS next Y4.54 Insider Trans-0.55% Shs Float509.80M Perf Month9.15%
Income225.90M PEG8.86 EPS next Q0.95 Inst Own87.30% Short Float3.25% Perf Quarter-29.66%
Sales11.24B P/S0.87 EPS this Y-57.40% Inst Trans0.01% Short Ratio2.18 Perf Half Y-35.80%
Book/sh23.09 P/B0.82 EPS next Y5.92% ROA0.70% Target Price29.53 Perf Year-47.63%
Cash/sh0.56 P/C33.70 EPS next 5Y4.90% ROE2.00% 52W Range16.63 - 39.59 Perf YTD-30.77%
Dividend- P/FCF6.99 EPS past 5Y-16.70% ROI3.50% 52W High-53.45% Beta1.77
Dividend %- Quick Ratio0.90 Sales past 5Y10.60% Gross Margin39.80% 52W Low10.82% ATR0.59
Employees35000 Current Ratio1.50 Sales Q/Q-7.00% Oper. Margin6.80% RSI (14)42.94 Volatility3.19% 2.98%
OptionableYes Debt/Eq1.16 EPS Q/Q-128.80% Profit Margin2.10% Rel Volume0.79 Prev Close18.97
ShortableYes LT Debt/Eq1.10 EarningsAug 06 BMO Payout0.00% Avg Volume7.61M Price18.43
Recom2.10 SMA20-2.00% SMA50-4.23% SMA200-33.19% Volume6,013,788 Change-2.85%
Jun-11-19Initiated Barclays Overweight $26
May-08-19Downgrade Wells Fargo Outperform → Market Perform $33 → $22
Mar-20-19Initiated SunTrust Buy $35
Mar-07-19Resumed UBS Neutral $31
Mar-06-19Upgrade Morgan Stanley Equal-Weight → Overweight $35
Feb-27-19Downgrade Bernstein Outperform → Mkt Perform $33
Jan-23-19Downgrade UBS Buy → Neutral
Nov-15-18Upgrade Argus Hold → Buy
Nov-06-18Upgrade BofA/Merrill Neutral → Buy
Oct-09-18Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-05-18Downgrade Mizuho Buy → Neutral
Aug-24-18Upgrade Evercore ISI In-line → Outperform
Aug-13-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Mar-15-18Reiterated Mizuho Buy $45 → $51
Mar-06-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-25-18Reiterated Susquehanna Positive $47 → $55
Jan-04-18Reiterated Citigroup Buy $48 → $58
Jan-03-18Initiated Leerink Partners Mkt Perform $44
Dec-12-17Initiated Guggenheim Buy $59
Jul-15-19 10:35AM  Morgan Stanley Downgrades Teva, Endo On Drug Pricing And Litigation Concerns Benzinga
07:30AM  Mapi Pharma to Build a New Sterile Injectable Production Plant for GA Depot in Jerusalem GlobeNewswire
Jul-14-19 11:10AM  Health companies start reporting earnings next week: Here are 3 things to keep in mind MarketWatch
Jul-11-19 04:21PM  Amneal (AMRX) Down on Guidance Update & Restructuring Plan Zacks
08:54AM  UPDATE 2-Walgreens expands epinephrine shot partnership as shortage persists Reuters
08:00AM  Pfizer Stock Is The Biggest Pharma But Should You Buy It? Investor's Business Daily
Jul-10-19 02:07PM  Theres Nothing to Give Them: The Hunt for Lifesaving Epipens Bloomberg
12:43PM  EpiPen Shortage: Mylan (MYL) Stock Falls on Continued Scarce Supply InvestorPlace
11:34AM  Here's Why Amneal Pharmaceuticals Fell as Much as 36.6% Today Motley Fool
09:22AM  Mylan Falls on Report That EpiPen Shortage Is Hurting Patients and Pharmacists
07:35AM  UPDATE 1-Amneal Pharma cuts core profit forecast on allergy shot supply issues Reuters
07:04AM  Amneal Pharma slashes core earnings forecast on allergy shot supply issues Reuters
Jul-09-19 03:55PM  Federal judge blocks Trump Administration's proposal to include wholesale drug prices in TV ads Yahoo Finance Video
12:32PM  DaVita Stock Is Dropping, Netflix Is Climbing, and the Dow Has Dropped 84 Points
11:54AM  UPDATE 3-Novartis to sell epinephrine shot in U.S. pharmacies amid EpiPen shortage Reuters
07:45AM  Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage Reuters
Jul-08-19 12:42PM  Mylan and Atomo Diagnostics Announce WHO Prequalification Approval for Mylan HIV Self Test PR Newswire
Jul-01-19 09:01AM  Here are the stock markets winners and losers in the first half of 2019 MarketWatch
Jun-26-19 08:08AM  Investors support stronger clawback provision for pay of Mylan executives American City Business Journals
Jun-25-19 11:39AM  Allergan acquisition is a major bailout for shareholders, according to analysts MarketWatch
08:00AM  Medexus Appoints Accomplished Global Pharmaceutical Industry Executive Adele M. Gulfo to its Board of Directors GlobeNewswire
07:42AM  Drug maker stocks rally after AbbVie's deal to buy Allergan for 45% premium MarketWatch
Jun-20-19 07:40AM  5 Undervalued Stocks to Buy InvestorPlace
Jun-14-19 08:05AM  Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories PR Newswire
Jun-13-19 04:12PM  Amgen, Biogen, Gilead and Novo Nordisk have very high capacity for M&A, says Moodys MarketWatch
Jun-12-19 06:29AM  Barclays Has New Plays for Healthcare Fans SmarterAnalyst
Jun-11-19 06:12PM  The Only Hope for Mylan Shareholders Appears to Be a Breakup or Sale
Jun-10-19 10:09AM  Heres What Hedge Funds Think About Mylan N.V. (MYL) Insider Monkey
Jun-07-19 01:59PM  UPDATE 1-CtW opposes re-election of members of Mylan board's governance panel Reuters
12:05PM  CtW urges Mylan shareholders to vote against board nominees for panel Reuters
Jun-06-19 09:31AM  Mylan (MYL) Down 18.8% Since Last Earnings Report: Can It Rebound? Zacks
Jun-04-19 04:21PM  How Much Could Generic Pharmas Have To Fork Over In Antitrust Lawsuit? Investor's Business Daily
May-31-19 01:53PM  How investor group started on quest for accountability from Mylan American City Business Journals
11:14AM  Mylan urged to boost clawback policy for senior executives' incentives American City Business Journals
May-29-19 09:42AM  Teva Settles With Oklahoma, Shares Fall Following Downgrade Zacks
08:55AM  Options Traders Expect Huge Moves in Mylan (MYL) Stock Zacks
07:38AM  The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation Benzinga
05:35AM  The 5 Worst Stocks So Far This Year
May-28-19 04:20PM  Pharma Giant Crashes To 19-Year Low On Generic Drugs Lawsuit Investor's Business Daily -5.69%
May-24-19 05:02PM  An Antitrust Lawsuit Could Cost Generic Pharmas Billions Of Dollars Investor's Business Daily
May-23-19 10:38AM  Amgen (AMGN) Offers to Acquire Drug Discovery Platform Zacks
May-20-19 10:15AM  Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference PR Newswire
07:15AM  Edited Transcript of MYL earnings conference call or presentation 7-May-19 2:00pm GMT Thomson Reuters StreetEvents
05:02AM  South Africa's Aspen sells Australian prescription portfolio to Mylan Reuters
04:08AM  South Africa's Aspen sells Australian prescription portfolio to Mylan Reuters
May-18-19 10:45AM  Mylan Presents Equivalence and Device Usability Data on Wixela Inhub Compared to Advair Diskus® at American Thoracic Society International Conference PR Newswire
May-17-19 08:00AM  Mylan to Host Investor Day on July 31, 2019 in New York City PR Newswire
May-16-19 08:00AM  Generic Drugs Are Stabilizing Can They Survive An Antitrust Scandal? Investor's Business Daily
May-15-19 05:01PM  Mylan and Biocon to Present Final Overall Survival Data for Ogivri (trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
11:47AM  Teva Hits Fibonacci Support on Concerns Over Lawsuit Investopedia
10:34AM  Here are the most and least volatile stocks since Trump ramped up trade conflict MarketWatch
10:30AM  Mylan's stock falls toward 7 1/2-year low; credit rating now in danger of downgrade to 'junk' at Fitch MarketWatch
09:24AM  The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer Zacks
07:46AM  AbbVie Settles Humira Litigation With Boehringer Ingelheim Zacks
May-14-19 04:00PM  There's misinformation out there on generic drugs: Association of Accessible Medicines CEO CNBC Videos
10:17AM  Here's Why Generic-Drug Manufacturers Were Down Monday Motley Fool
09:18AM  Generic Drugmakers Face Antitrust Suit Alleging Price Fixing Zacks
May-13-19 05:30PM  The Dow Plunges 617 Points Because China Is Hitting Back With Retaliatory Tariffs -9.43%
04:48PM  Here are Mondays worst stock-market performers as U.S.-China trade dispute escalates MarketWatch
04:41PM  Teva, 19 other drug companies accused of inflating drug prices Yahoo Finance Video
02:38PM  Drug price fixing allegation may be increasingly problematic for makers: Analyst CNBC Videos
02:10PM  Mylan Call Options Hot as Stock Hits New Low Schaeffer's Investment Research
12:42PM  Forty-four states accuse Teva Pharmaceutical of inflating drug prices CNBC Videos
11:30AM  2 Drug Stocks to Buy as Health Care Suffers, According to JPMorgan
10:00AM  Stocks Dive As China Trade War Worsens; Teva, Mylan Tanks On Lawsuits Investor's Business Daily
May-12-19 11:00PM  US generic drug companies hit by price-fixing claims Financial Times
May-11-19 12:39PM  This will likely end badly: Analysts react to Mylans revenue miss and earnings call MarketWatch
May-10-19 09:45AM  Mylan Expands Oncology Portfolio with Launch of Generic Tarceva® Tablets PR Newswire
08:00AM  Mylan to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference PR Newswire
May-09-19 04:09PM  Mylan Stock Jumps On Rumored Bid After Lackluster First Quarter Investor's Business Daily
May-08-19 11:44AM  Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates Zacks
09:30AM  Company News For May 8, 2019 Zacks
08:02AM  Here are the biggest analyst calls of the day: Pinterest, US Steel, Mylan & more CNBC
07:34AM  3 Big Stock Charts for Wednesday:, DISH Network and F5 Networks InvestorPlace
07:00AM  Market Morning: Mylan Massacre, Futures Dither, Meatless McDonalds, Uber Drivers Bash Greed, Want More Money Market Exclusive
02:16AM  Mylan/generic pharma: from heyday to mayday Financial Times
May-07-19 05:09PM  The Dow Slumped 473 Points Because No One Wins a Trade War -23.81%
04:58PM  AIG and SolarEdge rise while Mylan and Phibro fall Associated Press
04:32PM  Allergan Fended Off Botox Rivalries In The First Quarter But Can It Last? Investor's Business Daily
04:31PM  Mylan Suffers Biggest Drop in Almost Two Decades Amid Drug Pain Bloomberg
04:30PM  US STOCKS-Wall Street slides as U.S.-China trade fears rise Reuters
04:23PM  Mylan N.V. (MYL) Q1 2019 Earnings Call Transcript Motley Fool
03:21PM  Epipen Parent's Faceplant Is a Cautionary Tale for Botox Maker Bloomberg
03:04PM  Mylan Beats Estimates but Gets Slammed on Guidance Investopedia
03:00PM  Mylan's Struggles Continue in the First Quarter Motley Fool
02:59PM  US STOCKS-Wall Street extends decline as China trade worries mount Reuters
01:55PM  SeaWorld looks to Big Bird for help, Lyft drives toward earnings debut MarketWatch
01:51PM  Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss Zacks
01:35PM  Mylan notified that several states intend to file new complaint alleging anticompetitive conduct MarketWatch
01:30PM  'Near term' conclusion for Mylan strategic review American City Business Journals
01:15PM  Stocks making the biggest moves midday: Beyond Meat, Boeing, Mylan & more CNBC
01:04PM  Mylan Shares Tumble on Disappointing Revenue
12:57PM  US STOCKS-Wall Street extends fall as U.S-China trade worries mount Reuters
12:45PM  Mylan Tanks After First-Quarter Revenue Misses Estimates
12:29PM  Mylan gives no clear view on strategic options, shares plunge 17 percent Reuters
11:45AM  US STOCKS-Wall Street plunges on heightening U.S.-China trade worries Reuters
11:44AM  Why Mylan Stock Is Sinking Today Motley Fool
10:23AM  US STOCKS-Wall Street declines on U.S.-China trade tensions Reuters
09:45AM  Mylan (MYL) Surpasses Q1 Earnings Estimates Zacks
08:58AM  Mylan shares down 4.5% after drugmaker misses on revenue MarketWatch
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; TB Alliance; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COURY ROBERT JDirectorJun 24Option Exercise0.00750,00001,309,835Jun 25 08:04 PM
Gallagher Daniel Martin JrChief Legal OfficerApr 01Option Exercise0.008,515021,133Apr 03 06:00 PM
Campbell PaulSee RemarksMar 04Sale27.5011,533317,14324,137Mar 05 06:15 PM
BRESCH HEATHER MChief Executive OfficerMar 03Option Exercise0.0020,1420394,503Mar 05 06:06 PM
Gallagher Daniel Martin JrChief Legal OfficerMar 03Option Exercise0.008,218016,567Mar 05 06:09 PM
Mauro AnthonyChief Commercial OfficerMar 03Option Exercise0.005,534098,537Mar 05 06:11 PM
Malik RajivPresidentMar 03Option Exercise0.0012,3950275,388Mar 05 06:11 PM
Parks Kenneth ScottChief Financial OfficerMar 03Option Exercise0.003,984016,853Mar 05 06:13 PM
Campbell PaulSee RemarksMar 03Option Exercise0.002190599Mar 05 06:15 PM
Campbell PaulSee RemarksMar 03Option Exercise0.00830024,493Mar 05 06:15 PM
Campbell PaulSee RemarksMar 02Option Exercise0.001670437Mar 05 06:15 PM
Campbell PaulSee RemarksMar 02Option Exercise0.001,980024,540Mar 05 06:15 PM
Parks Kenneth ScottChief Financial OfficerMar 02Option Exercise0.006,103015,541Mar 05 06:13 PM
Malik RajivPresidentMar 02Option Exercise0.0014,6450269,457Mar 05 06:11 PM
Mauro AnthonyChief Commercial OfficerMar 02Option Exercise0.006,103095,657Mar 05 06:11 PM
Gallagher Daniel Martin JrChief Legal OfficerMar 02Option Exercise0.007,811012,093Mar 05 06:09 PM
BRESCH HEATHER MChief Executive OfficerMar 02Option Exercise0.0022,2120384,223Mar 05 06:06 PM
Vollebregt Sjoerd SDirectorMar 02Option Exercise0.004,02808,258Mar 05 06:33 PM
VANDERVEEN RANDALL LDirectorMar 02Option Exercise0.004,028045,845Mar 05 06:30 PM
van der Meer Mohr PaulineDirectorMar 02Option Exercise0.004,56604,566Mar 05 06:27 PM
PARRISH MARK WDirectorMar 02Option Exercise0.004,028041,423Mar 05 06:25 PM
KORMAN HARRYDirectorMar 02Option Exercise0.004,566024,816Mar 05 06:23 PM
HIGGINS MELINA EDirectorMar 02Option Exercise0.004,028013,120Mar 05 06:22 PM
DIMICK NEIL FDirectorMar 02Option Exercise0.004,028048,645Mar 05 06:21 PM
Lyons Dillon JoEllenDirectorMar 02Option Exercise0.004,028013,667Mar 05 06:20 PM
Cindrich Robert JDirectorMar 02Option Exercise0.004,028023,107Mar 05 06:16 PM
Malik RajivPresidentFeb 19Option Exercise0.0014,5890584,940Feb 21 06:01 PM
Parks Kenneth ScottChief Financial OfficerFeb 19Option Exercise0.004,837011,550Feb 21 06:00 PM
BRESCH HEATHER MChief Executive OfficerFeb 19Option Exercise0.0025,2870751,359Feb 21 06:00 PM
Campbell PaulSee RemarksFeb 19Option Exercise0.001,216023,157Feb 21 06:00 PM
Mauro AnthonyChief Commercial OfficerFeb 19Option Exercise0.007,9430160,520Feb 21 06:00 PM
Malik RajivPresidentFeb 17Option Exercise0.0022,0240579,185Feb 20 06:02 PM
Parks Kenneth ScottChief Financial OfficerFeb 17Option Exercise0.002,14907,733Feb 20 06:00 PM
Campbell PaulSee RemarksFeb 17Option Exercise0.00540022,207Feb 20 06:00 PM
Mauro AnthonyChief Commercial OfficerFeb 17Option Exercise0.009,0150156,699Feb 20 05:00 PM
BRESCH HEATHER MChief Executive OfficerFeb 17Option Exercise0.0037,0940742,601Feb 20 05:01 PM